Celestica is rated a buy, driven by strong growth in customized solutions across ATS and CCS segments, especially AI-related HPS products. CLS demonstrates accelerating revenue and profit growth, ...

Celestica (CLS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Celestica is downgraded to Hold from Buy due to limited upside and stretched valuation after a strong rally. CLS's business momentum remains robust, driven by rapid growth in its High-Performance ...

Clinisys expands laboratory innovation with the launch of CLS v2025.2, delivering breakthrough healthcare capabilities with tailored solutions for Clinical Pathology and Genomics labs in North America ...

What makes student residents remember a space? It’s personalization, argues Elliot Tamir, co-founder & co-CEO of CLS Living. That individual attention needs to come through in their daily experience.

We recently published Monstrous Gains: 10 Stocks Leaving Wall Street in the Dust. Celestica Inc. (NYSE:CLS) is one of the best performers on Friday. Celestica soared to a new all-time high on Friday, ...

Abstract: The goal of this project is to develop a Film Tip Engine utilizing the power of Expert-System, Deep Learning, Computational Linguistics (CLs). The system utilizes Python's programming ...

CLS Global admitted to helping wash trade and manipulate the market for a token made by the FBI designed to draw in those engaged in fraudulent crypto activities. A crypto financial services firm has ...

Celestica Inc. CLS has gained a phenomenal 241.8% over the past year compared with the electronics manufacturing services industry’s growth of 54.4%. It has also outperformed peers like Flex Ltd. FLEX ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected for a variety of common eye diseases, Clearside Biomedical is making ...